Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CTSV | O60911 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.55 |
| ▸ | PARP1 | P09874 | 2/20 | 0.55 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.51 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.51 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.51 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31169728 | 1.00 | CA12 (0.58) | CA12CA9CTSVCTSLPARP1 | |
| SCHEMBL3604526 | 0.87 | PARP1 (0.58) | CA12CA9CTSVCTSLPARP1 | |
| SCHEMBL30349881 | 0.82 | MAPT (0.61) | CA12CA9CTSVCTSLPARP1 | |
| SCHEMBL31081636 | 0.81 | CA12 (0.58) | CA12CA9CTSVCTSLPARP1 | |
| SCHEMBL4469615 | 0.81 | CA12 (0.58) | CA12CA9CTSVCTSLPARP1 | |
| SCHEMBL29540314 | 0.79 | GABRA1 (0.70) | CA12CA9CTSVCTSLPARP1 | |
| SCHEMBL155013 | 0.79 | GABRA1 (0.70) | CA12CA9CTSVCTSLPARP1 | |
| SCHEMBL8366377 | 0.78 | CA12 (0.51) | CA12CA9CTSVCTSLPARP1 | |
| SCHEMBL31254142 | 0.77 | CTSV (0.60) | CA12CA9CTSVCTSLPARP1 | |
| SCHEMBL28982709 | 0.77 | ALDH1A1 (0.59) | CA12CA9CTSVCTSLPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729127-A2 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042776-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12486285-B2 | BCL6 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-12-02 | — | — | US | disclosed |
| EP-3630749-B9 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-4371562-A2 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2024-05-22 | — | — | EP | disclosed |
| EP-3630749-B1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-20230287003-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-14 | — | — | US | disclosed |
| EP-4201939-A1 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2023-06-28 | — | — | EP | disclosed |
| EP-3774817-B1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2022-12-07 | — | — | EP | disclosed |
| US-11512095-B2 | BCL6 inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-11-29 | — | — | US | disclosed |
| CN-112334475-A | BCL6 inhibitor | 癌症研究技术有限公司 | 2021-02-05 | — | — | CN | disclosed |
| EP-3327004-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORP (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-10696637-B2 | Nitrogen-containing heterocyclic compound | FUJIFILM CORPORATION (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10633343-B2 | — | — | 2020-04-28 | — | — | US | disclosed |
| EP-3630749-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| EP-3563851-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM Corporation (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-20190314360-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM CORPORATION (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20190077761-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| WO-2018215798-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
| EP-3327004-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Fujifilm Corporation (JP) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287003-A1 | BCL6 INHIBITORS | BCL6, BCL6B, BCL3 | CA12 4340/4885CA9 3945/4885CTSV 2198/4885 |
| US-10696637-B2 | Nitrogen-containing heterocyclic compound | CXCL10, CCL5, CXCR3 | CA12 1029/4885CA9 1127/4885CTSV 4051/4885 |
| US-12486285-B2 | BCL6 inhibitors | BCL6, BCL6B, BCL3 | CA12 4340/4885CA9 3945/4885CTSV 2198/4885 |
| US-20190314360-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | BRD4, BRD1, BRD3 | CA12 998/4885CA9 1004/4885CTSV 2049/4885 |
| US-20190077761-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CXCL10, CCL5, CXCR3 | CA12 1029/4885CA9 1127/4885CTSV 4051/4885 |
| US-11512095-B2 | BCL6 inhibitors | BCL6, BCL6B, BCL3 | CA12 4340/4885CA9 3945/4885CTSV 2198/4885 |
| US-20260042776-A1 | BCL6 INHIBITORS | BCL6, BCL6B, BCL9 | CA12 4101/4885CA9 2157/4885CTSV 1898/4885 |
| US-10633343-B2 | — | CXCL10, CCL5, CXCR3 | CA12 874/4885CA9 1121/4885CTSV 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.